Motiva Flora® Tissue Expander as a Support for the Creation of an Autologous Adipose Matrix for Hybrid Breast Reconstruction: a Pivotal Study

Status: Recruiting
Location: See all (4) locations...
Intervention Type: Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The present study will be based on a hybrid breast reconstruction approach with initial skin expansion using the Motiva Flora® Tissue Expander followed by a serial fat grafting session and a final step that includes the placement of a permanent breast implant Ergonomix2®.

Eligibility
Participation Requirements
Sex: Female
Minimum Age: 18
Healthy Volunteers: f
View:

• Genetically female, aged 18 years or older.

• Subjects who had provided written informed consent form.

• The participant needs tissue expansion as part of breast reconstruction treatment, which may include immediate reconstruction.

• Clinical condition to allow reverse expansion breast reconstruction, at the investigator's discretion.

• Sufficient fat in donor sites (abdomen, gluteus, hips, and thighs) per plastic surgeon criteria.

• Complete radiotherapy and chemotherapy at least one year before surgery.

• BMI between 18.5 and 30.0 (average classified weight).

• Physical and cognitive capacity to understand and follow the surgeon's recommendations.

• To be able and willing to comply with all study requirements, including attending follow-up appointments.

• Only Sub study participants

⁃ Provide additional consent to undergo an MRI with contrast.

Locations
Other Locations
Belgium
Universitair Ziekenhuis Gent
RECRUITING
Ghent
Colombia
Hospital Universitario San Ignacio
NOT_YET_RECRUITING
Bogotá
Costa Rica
Hospital UNIBE
NOT_YET_RECRUITING
San José
Spain
Hospital de la Santa Creu i Sant Pau
RECRUITING
Barcelona
Contact Information
Primary
Lilián Patricia Palma López
lpalma@establishmentlabs.com
+34649713486
Backup
Laura García Jimenez
lgarcia@establishmentlabs.com
Time Frame
Start Date: 2023-08-18
Estimated Completion Date: 2027-04
Participants
Target number of participants: 66
Sponsors
Leads: Establishment Labs
Collaborators: NAMSA

This content was sourced from clinicaltrials.gov